RIO DE JANEIRO, BRAZIL - According to the vote of Director Meiruze Freitas, the drug does not meet the health regulator Anvisa's expectations in terms of minimum safety and efficacy requirements in the context of emergency use.
"You cannot approve the use of a drug that has not shown clinical benefit in the treatment of Covid-19 and yet can lead to health risks for patients," she said.
The drug, manufactured by Russian companies API - Technologies LLC and Joint Stock Company Chemical Diversity Research Institute - JSC CDRI, had registered the application for emergency use approval by the Vital Brazil Institute . . .